Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19

The emergence and rapid spread of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in thelate 2019 has caused a devastating global pandemic of the severe pneumonia-like disease coronavirus disease ...

Source: BMC Clinical Pharmacology - October 21, 2021 Category: Drugs & Pharmacology Authors: Maral Aminpour, Williams Ernesto Miranda Delgado, Soren Wacker, Sergey Noskov, Michael Houghton, D. Lorne J. Tyrrell and Jack A. Tuszynski Tags: Research Source Type: research